365 results on '"Kugathasan, S."'
Search Results
2. African Ancestry Proportion Influences Ileal Gene Expression in Inflammatory Bowel Disease
Catalog
Books, media, physical & digital resources
3. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease
4. DOP015 Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn disease
5. DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
6. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
7. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
8. Production of IL12p70 and IL23 by monocyte-derived dendritic cells in children with inflammatory bowel disease
9. Genetic variants in the autophagy pathway contribute to paediatric Crohn’s disease
10. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease
11. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
12. Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD
13. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
14. IBD Serology and Disease Outcomes in African Americans with Crohn's Disease
15. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes:a genetic association study
16. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
17. 16 - Safety and Efficacy of Autologous and Metabolically Fit Bone Marrow Mesenchymal Stromal Cells (BM-MSC) in Medically Refractory Crohn's Disease (CD)
18. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses.
19. Authors' reply
20. O-11: Real world outcomes of contemporary treatments in children with Crohn’s disease: observations from the pediatric IBD collaborative research group registry
21. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis
22. P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data
23. 15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data
24. Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease.
25. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.
26. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity.
27. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
28. Stool microbiome communities predict remission in pediatric Crohn’s Disease patients even after start of treatment.
29. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.
30. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts.
31. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
32. Pediatric inflammatory bowel disease: clinical and therapeutic aspects.
33. S03 Association of DYM gene with growth impairment in pediatric Crohn's disease
34. P192 - Disease duration does not affect outcome following infliximab therapy in children with Crohn's disease
35. P014 ANTI-INFLAMMATORY ROLE OF IL-27 IN TNF-ALPHA INDUCED INTESTINAL INFLAMMATION
36. O07 PREDICTORS OF CLINICAL OUTCOME IN CHILDREN WITH ULCERATIVE COLITIS (UC)
37. P044 RETROSPECTIVE EVALUATION OF THE SAFETY AND EFFECT OF ADALIMUMAB THERAPY (RESEAT) IN PEDIATRIC CROHN'S DISEASE
38. Improvement in a biomarker of bone formation during infliximab therapy in pediatric Crohn disease: Results of the REACH study
39. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis
40. Infliximab binds human monocytes but not mucosal T cells in vitro: No direct anti-T cell mechanism of action
41. Commentaries on 'Workshop Report: Developing a Pediatric Inflammatory Bowel Diseases Network and Data Platform in Canada': PEDIATRIC INFLAMMATORY BOWEL DISEASE NETWORKS: RAISING THE BAR.
42. Genetic variants in the autophagy pathway contribute to paediatric Crohn's disease.
43. The Effects of Infliximab Therapy on Health-Related Quality of Life in Pediatric Crohn's Disease.
44. O0106 THE INCIDENCE AND PREVALENCE OF PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) IN THE USA.
45. Successful resuscitation of a child after exsanguination due to aortoesophageal fistula from undiagnosed foreign body.
46. Rising incidence of inflammatory bowel disease in young children: what does the future hold?
47. Linear Growth During Infliximab Therapy: Results of the REACH Multicenter Study.
48. Improvement in a Biomarker of Bone Formation during Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study.
49. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings.
50. P0712 RE-EVALUATION OF THE PEDIATRIC CROHN’S DISEASE ACTIVITY INDEX: USEFULNESS IN THE PRACTICE SETTING.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.